WO2003068224A3 - Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen - Google Patents

Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen Download PDF

Info

Publication number
WO2003068224A3
WO2003068224A3 PCT/EP2003/001100 EP0301100W WO03068224A3 WO 2003068224 A3 WO2003068224 A3 WO 2003068224A3 EP 0301100 W EP0301100 W EP 0301100W WO 03068224 A3 WO03068224 A3 WO 03068224A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
bicarbonate
exchanger
sodium
inflammatory diseases
Prior art date
Application number
PCT/EP2003/001100
Other languages
English (en)
French (fr)
Other versions
WO2003068224A2 (de
Inventor
Hans-Jochen Lang
Heinz-Werner Kleemann
Stefan Werner Schneider
Hans Oberleithner
Andre Niemeyer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Priority to JP2003567406A priority Critical patent/JP2005525338A/ja
Priority to AU2003208792A priority patent/AU2003208792A1/en
Priority to BR0307637-7A priority patent/BR0307637A/pt
Priority to CA002476454A priority patent/CA2476454A1/en
Priority to MXPA04007007A priority patent/MXPA04007007A/es
Priority to EP03706428A priority patent/EP1476154A2/de
Publication of WO2003068224A2 publication Critical patent/WO2003068224A2/de
Publication of WO2003068224A3 publication Critical patent/WO2003068224A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)

Abstract

Inhibitoren des zellulären Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zeigen eine inhibierende Wirkung auf die Sekretion des von-Willebrand-Faktors. Diese Inhibitoren können daher zur Behandlung von thrombotischen und inflammatorischer Erkrankungen eingesetzt werden.
PCT/EP2003/001100 2002-02-14 2003-02-05 Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen WO2003068224A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2003567406A JP2005525338A (ja) 2002-02-14 2003-02-05 血栓性および炎症性障害の治療のためのナトリウム依存性クロライド／バイカーボネート交換体の阻害剤の使用
AU2003208792A AU2003208792A1 (en) 2002-02-14 2003-02-05 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
BR0307637-7A BR0307637A (pt) 2002-02-14 2003-02-05 Aplicação de inibidores do trocador cloreto-bicarbonato dependente de sódio para o tratamento de doenças trombóticas e inflamatórias
CA002476454A CA2476454A1 (en) 2002-02-14 2003-02-05 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
MXPA04007007A MXPA04007007A (es) 2002-02-14 2003-02-05 Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.
EP03706428A EP1476154A2 (de) 2002-02-14 2003-02-05 Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10206354A DE10206354A1 (de) 2002-02-14 2002-02-14 Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
DE10206354.0 2002-02-14

Publications (2)

Publication Number Publication Date
WO2003068224A2 WO2003068224A2 (de) 2003-08-21
WO2003068224A3 true WO2003068224A3 (de) 2003-12-24

Family

ID=27634996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001100 WO2003068224A2 (de) 2002-02-14 2003-02-05 Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen

Country Status (10)

Country Link
EP (1) EP1476154A2 (de)
JP (1) JP2005525338A (de)
AR (1) AR038837A1 (de)
AU (1) AU2003208792A1 (de)
BR (1) BR0307637A (de)
CA (1) CA2476454A1 (de)
DE (1) DE10206354A1 (de)
MX (1) MXPA04007007A (de)
TW (1) TW200306808A (de)
WO (1) WO2003068224A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359640B (es) 2010-11-05 2018-10-04 Senomyx Inc Compuestos utiles como moduladores de trpm8.
US10392371B2 (en) 2015-10-01 2019-08-27 Senomyx, Inc. Compounds useful as modulators of TRPM8

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903339A2 (de) * 1997-09-22 1999-03-24 Hoechst Marion Roussel Deutschland GmbH Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
WO1999040064A1 (de) * 1998-02-04 1999-08-12 Aventis Pharma Deutschland Gmbh Biphenylsulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
WO1999057102A1 (de) * 1998-05-06 1999-11-11 Aventis Pharma Deutschland Gmbh Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
WO2000003994A2 (de) * 1998-07-18 2000-01-27 Aventis Pharma Deutschland Gmbh Imidazolderivate mit biphenylsulfonylsubstitution, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
WO2000003996A1 (de) * 1998-07-18 2000-01-27 Aventis Pharma Deutschland Gmbh Imidazolderivate mit biphenylsulfonylsubstitution, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903339A2 (de) * 1997-09-22 1999-03-24 Hoechst Marion Roussel Deutschland GmbH Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
WO1999040064A1 (de) * 1998-02-04 1999-08-12 Aventis Pharma Deutschland Gmbh Biphenylsulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
WO1999057102A1 (de) * 1998-05-06 1999-11-11 Aventis Pharma Deutschland Gmbh Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
WO2000003994A2 (de) * 1998-07-18 2000-01-27 Aventis Pharma Deutschland Gmbh Imidazolderivate mit biphenylsulfonylsubstitution, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
WO2000003996A1 (de) * 1998-07-18 2000-01-27 Aventis Pharma Deutschland Gmbh Imidazolderivate mit biphenylsulfonylsubstitution, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum

Also Published As

Publication number Publication date
CA2476454A1 (en) 2003-08-21
EP1476154A2 (de) 2004-11-17
BR0307637A (pt) 2005-01-04
AR038837A1 (es) 2005-01-26
AU2003208792A1 (en) 2003-09-04
JP2005525338A (ja) 2005-08-25
MXPA04007007A (es) 2004-10-11
DE10206354A1 (de) 2003-08-28
TW200306808A (en) 2003-12-01
WO2003068224A2 (de) 2003-08-21

Similar Documents

Publication Publication Date Title
WO2004030625A3 (en) Synergistic methods and compositions for treating cancer
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
IL158559A0 (en) Acne treatment
WO2003088897A3 (en) Fab i inhibitors
SI2298338T1 (sl) Laktoferinski sestavki in postopki za zdravljenjekožnih ran
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
AU2003209851A1 (en) Method of treatment and/or prophylaxis
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
HK1073438A1 (en) Furin inhibitors for use in the treatment of fibrosis and scarring
AU2003211009A1 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
PL378325A1 (pl) Kompozycja do stosowania miejscowego i sposoby leczenia skóry starzejącej się lub uszkodzonej przez środowisko
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
AU2002346594A1 (en) Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
WO2003068224A3 (de) Verwendung von inhibitoren des natrium-abhängigen chlorid-bicarbonat-austauschers zur behandlung von thrombotischen und inflammatorischer erkrankungen
AU2003237150A1 (en) Compositions and methods for treating inflammatory connective tissue diseases
WO2005013946A3 (en) Methods of treatment inflammatory bowel with lxr agonists
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
AU2003265281A8 (en) Methods and compositions for the enhancement of wound healing
TW200642688A (en) New use of PDE7 inhibitors
WO2005077019A3 (en) Protease inhibitors for treatment of wrinkles
DE602004012759D1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007007

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003706428

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003567406

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2476454

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2003706428

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2003706428

Country of ref document: EP